- Home
- ORGO vs HBCP Comparison
ORGO vs HBCP Comparison
Compare ORGO & HBCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORGO
- HBCP
- Stock Information
- Founded
- ORGO 1985
- HBCP 1908
- Country
- ORGO United States
- HBCP United States
- Employees
- ORGO N/A
- HBCP N/A
- Industry
- ORGO Biotechnology: Pharmaceutical Preparations
- HBCP Banks
- Sector
- ORGO Health Care
- HBCP Finance
- Exchange
- ORGO Nasdaq
- HBCP Nasdaq
- Market Cap
- ORGO 376.8M
- HBCP 342.0M
- IPO Year
- ORGO N/A
- HBCP 2008
- Fundamental
- Price
- ORGO $2.92
- HBCP $49.39
- Analyst Decision
- ORGO Buy
- HBCP Buy
- Analyst Count
- ORGO 2
- HBCP 2
- Target Price
- ORGO $5.50
- HBCP $57.50
- AVG Volume (30 Days)
- ORGO 1.6M
- HBCP 36.9K
- Earning Date
- ORGO 05-08-2025
- HBCP 07-16-2025
- Dividend Yield
- ORGO N/A
- HBCP 2.09%
- EPS Growth
- ORGO N/A
- HBCP 0.90
- EPS
- ORGO N/A
- HBCP 4.78
- Revenue
- ORGO $458,760,000.00
- HBCP $135,421,000.00
- Revenue This Year
- ORGO $2.73
- HBCP $0.25
- Revenue Next Year
- ORGO $12.28
- HBCP $5.18
- P/E Ratio
- ORGO N/A
- HBCP $10.46
- Revenue Growth
- ORGO 5.35
- HBCP 3.44
- 52 Week Low
- ORGO $2.28
- HBCP $35.16
- 52 Week High
- ORGO $6.71
- HBCP $52.77
- Technical
- Relative Strength Index (RSI)
- ORGO 35.44
- HBCP 51.68
- Support Level
- ORGO $2.61
- HBCP $49.42
- Resistance Level
- ORGO $3.28
- HBCP $51.00
- Average True Range (ATR)
- ORGO 0.14
- HBCP 1.25
- MACD
- ORGO 0.01
- HBCP -0.27
- Stochastic Oscillator
- ORGO 34.59
- HBCP 43.42
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
About HBCP Home Bancorp Inc.
Home Bancorp Inc is engaged in attracting deposits from the public and using those funds to invest in loans and securities. The principal sources of funds are customer deposits, repayments of loans, repayments of investments and funds borrowed from outside sources such as the Federal Home Loan Bank of Dallas. These funds are used for the origination of loans, including one-to-four-family first mortgage loans, home equity loans, and lines, commercial real estate loans, construction and land loans, multi-family residential loans, commercial and industrial loans, and consumer loans.